



Pataday® Once Daily Relief, Pataday Twice Daily Relief (olopatadine) – New over-the-counter approvals

- On February 14, 2020, the [FDA announced](#) the [approval](#) of over-the-counter (OTC) use of [Alcon's Pataday Once Daily Relief \(olopatadine\)](#) 0.2% ophthalmic solution for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander, and Pataday Twice Daily Relief (olopatadine) 0.1% ophthalmic solution for the temporary relief of itchy and red eyes due to pollen, ragweed, grass, animal hair and dander.
 - Previously, Pataday Once Daily Relief was available [generically](#) and under the brand name [Pataday](#) as prescription for the treatment of ocular itching associated with allergic conjunctivitis.
 - Previously, Pataday Twice Daily Relief was available [generically](#) and under the brand name [Patanol](#)® as prescription for the treatment of the signs and symptoms of allergic conjunctivitis.
- Itchy eye is the most common symptom of ocular allergies. About 66 million Americans are affected by ocular allergies.
- Olopatadine is a mast cell stabilizer, which works by preventing the release of histamine and therefore prevents or controls allergic disorders.
- Patients should stop use of OTC Pataday Once Daily Relief or Pataday Twice Daily Relief and consult a doctor if they experience eye pain, changes in vision, increased redness of the eye, or itching that worsens or lasts for more than 72 hours.
- The recommended dosage regimen for Pataday Once Daily Relief in adults and children 2 years of age and older is 1 drop in the affected eye(s) once daily, no more than once per day.
- The recommended dosage regimen for Pataday Twice Daily Relief in adults and children 2 years of age and older is one drop in the affected eye(s) twice daily, every 6 to 8 hours, no more than twice per day.
- Alcon plans to launch Pataday Once Daily Relief and Pataday Twice Daily Relief on March 2, 2020. Pataday Once Daily Relief will be available as a 0.2% ophthalmic solution and Pataday Twice Daily Relief will be available as a 0.1% ophthalmic solution.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.